



# Interagency Coordinating Committee on the Validation of Alternative Methods

## Ocular and Dermal Irritation Implementation Plan

Jill Merrill, Ph.D.

FDA, Center for Drug Evaluation and Research


ICCVAM Public Forum

May 24, 2018

Agency for Toxic Substances and Disease Registry • Consumer Product Safety Commission • Department of Agriculture  
Department of Defense • Department of Energy • Department of the Interior • Department of Transportation  
Environmental Protection Agency • Food and Drug Administration • National Institute for Occupational Safety and Health  
National Institutes of Health • National Cancer Institute • National Institute of Environmental Health Sciences Institute • National  
Institute of Standards and Technology • Occupational Safety and Health Administration

# Implementation Plan Outline

- Coordinate activities via ICCVAM Workgroups
- Draft a scoping document to identify U.S. agency requirements, needs, and decision contexts
- Coordinate efforts with stakeholders
- Identify, acquire, and curate high quality data from reference test methods
- Identify and evaluate non-animal alternative approaches
- Gain regulatory acceptance and facilitate use of non-animal approaches



# Ocular and Dermal Implementation Plan:

- Coordinate activities via ICCVAM Workgroups
- Draft a scoping document to identify U.S. agency requirements, needs, and decision contexts for Ocular and Dermal data
- Coordinate efforts with stakeholders
- Identify, acquire, and curate high quality data from reference test methods
- Identify and evaluate non-animal alternative approaches to Ocular and Dermal testing
- Gain regulatory acceptance and facilitate use of non-animal approaches

# Current Ocular and Dermal Irritation Workgroup Roster

- Adrienne Layton (CPSC)
- Joanna Matheson (CPSC)
- David Mattie (DOD)
- Timothy Varney (DOD)
- Evisabel Craig (EPA, OPP)
- Krystle Yozzo (EPA, OPP)
- Jenny Tao (EPA, OPP)
- Todd Stedeford (EPA, OPPT)
- Jill Merrill (FDA, CDER, WG Chair)
- Andrew J. McDougal (FDA, CDER)
- Donnie Lowther (FDA, CFSAN)
- Warren Casey (NIEHS)
- Elizabeth Maull (NIEHS)

## ICATM Liaison Members



- João Barroso (EURL ECVAM)
- Yavinder Bhuller (Health Canada)
- Brenda Linke (Health Canada)

## NICEATM Support Staff (ILS)

- Amber Daniel
- Neepa Choksi
- David Allen

## Validation Study: OptiSafe Method

- Manufactured kit for ocular irritant/non-irritant classification
- Irritation prediction based on measured molecular damage
- 2-Phase Validation Study
  - Bottom-up approach (non-irritants vs all irritant classes)
  - Phase I: Initial qualification of naïve labs and protocol refinement
  - Phase II: Testing of 30 chemicals by all 3 labs, additional 60 tested by main lab
- Testing complete – finalizing report
- ICCVAM ODIWG members make up the VMT




# Ocular and Dermal Implementation Plan:

- Coordinate activities via the ICCVAM Workgroups
- **Draft a scoping document to identify U.S. agency requirements, needs, and decision contexts for Ocular and Dermal data**
- Coordinate efforts with stakeholders
- Identify, acquire, and curate high quality data from reference test methods
- Identify and evaluate non-animal alternative approaches to Ocular and Dermal testing
- Gain regulatory acceptance and facilitate use of non-animal approaches

# Eye/Skin Irritation and Corrosion: U.S. Statutes and Regulations

| US Statute/Regulations   | Agency |
|--|--------|
| Federal Hazardous Substances Act (FHSA) (1960): 16 CFR 1500.3: <b>Consumer Products</b><br>Poison Prevention Packaging Act (1970): 16 CFR 1700: <b>Hazardous Household Substances</b>                            | CPSC   |
| Federal Hazardous Material Transportation Act (1975): 49 CFR 173.132, 49 CFR 173.137: <b>Transported Substances</b>  | DOT    |
| Federal Insecticide, Fungicide, and Rodenticide Act (U.S.C. Title 7, Chapter 6): 40 CFR 156, 40 CFR 158.500, 40 CFR 158.2140, 40 CFR 158.2230, 40 CFR 159.165: <b>Pesticides</b>                                 | EPA    |
| Toxic Substances Control Act (TSCA; 1976): 40 CFR 720.50: <b>New or Imported Chemicals</b>   | EPA    |
| Federal Food, Drug, and Cosmetic Act (1938): 21 CFR 807.92(b)(1): <b>Biologics other than those regulated by CDER</b>  | FDA    |
| Federal Food, Drug, and Cosmetic Act (1938): <b>All routes of administration for small molecule drugs, protein therapeutics, and monoclonal antibodies</b>   | FDA    |
| Federal Food, Drug, and Cosmetic Act (1938): <b>Medical devices and radiation-emitting products</b>  | FDA    |
| Federal Food, Drug, and Cosmetic Act (1938): 21 C.F.R. §170, 21 C.F.R. §73, 21 C.F.R. §74, 21 C.F.R. §700, 21 C.F.R. §701, 21 C.F.R. §710, 21 C.F.R. §720, 21 C.F.R. §740: <b>Food ingredients and cosmetics</b> | FDA    |
| Occupational Safety and Health Act (1970): 29 CFR 1910.1200: <b>Workplace materials and hazards</b>  | OSHA   |

# Agencies that Use Ocular and Dermal Data





# Ocular and Dermal Implementation Plan:

- Coordinate activities via the ICCVAM Workgroups
- Draft a scoping document to identify U.S. agency requirements, needs, and decision contexts for Ocular and Dermal data
- **Coordinate efforts with stakeholders**
- Identify, acquire, and curate high quality data from reference test methods
- Identify and evaluate non-animal alternative approaches to Ocular and Dermal testing
- Gain regulatory acceptance and facilitate use of non-animal approaches

## Eye Irritation: Private-Public Partnership

- Crop Life America-EPA-NICEATM
  - BASF, Dow, Bayer, Syngenta, Dupont
- Paired data for approximately 200 pesticides
- Rabbit eye test data + in vitro data in one or more assays:
  - Bovine corneal opacity and permeability (BCOP, OECD TG 437)
  - Isolated chicken eye (ICE, OECD TG 438)
  - EpiOcular (EO, OECD TG 492 and ET40 protocol)
  - Neutral red release (NRR)
  - Chorioallantoic membrane vascular assay (CAMVA)

## Outcome

- A tiered approach using EO and NRR is promising, but not sufficient to identify all hazard categories
- BCOP did not appear to be useful for testing agrochemical formulations
- ICE and CAMVA datasets were too small for definitive assessments
- Overall, there is a need to conduct prospective *in vitro* testing
  - Protocol optimization
  - Data generation for specific formulation types

## Skin Irritation: Private-Public Partnership

- Optimization of 3D skin model for testing antimicrobial cleaning products (AMCPs)
- Companies donated AMCPs
- Optimization/testing ongoing at IIVS
- Regular stakeholder teleconferences to discuss updates, data needs, etc.
  - PISC, PCRIM
  - EPA and NTP
  - Industry

# Ocular and Dermal Implementation Plan:

- Coordinate activities via the ICCVAM Workgroups
- Draft a scoping document to identify U.S. agency requirements, needs, and decision contexts for Ocular and Dermal data
- Coordinate efforts with stakeholders
- **Identify, acquire, and curate high quality data from reference test methods**
- Identify and evaluate non-animal alternative approaches to Ocular and Dermal testing
- Gain regulatory acceptance and facilitate use of non-animal approaches

# Ongoing Ocular and Dermal Irritation Data Collection/Curation

- EPA FIFRA
- CropLife America (paired in vivo and in vitro ocular)
- Other stakeholders (EPA-led stakeholder discussions)
- Developing and evaluating QSAR models and where feasible to use in defined approaches

# Ocular and Dermal Implementation Plan:

- Coordinate activities via the ICCVAM Workgroups
- Draft a scoping document to identify U.S. agency requirements, needs, and decision contexts for Ocular and Dermal data
- Coordinate efforts with stakeholders
- Identify, acquire, and curate high quality data from reference test methods
- **Identify and evaluate non-animal alternative approaches to ocular and dermal testing**
- Gain regulatory acceptance and facilitate use of non-animal approaches

# Prospective Testing of Agrochemical Formulations

- Phase 1: small number (n=6) tested in all assays to demonstrate proof-of-concept
- Phase 2: comprehensive assessment of applicability with a larger set
  - Phase 2 study design and assays to be included contingent on Phase 1 results
- Coded formulations donated by companies
- Careful consideration of in vivo data
- Co-organized by NICEATM and PISC, with VMT members from ICCVAM and ODIWG, EURL ECVAM, PMRA, and industry



# Eye Methods to be Evaluated

- BCOP
- ICE
- NRR
- EpiOcular (time to toxicity and TG 492 protocols)
- PorCORA (to evaluate reversibility of effects)
  
- Phase 1 testing ongoing

## Additional Efforts


- Investigate the feasibility of developing new approaches, particularly for classes of substances that are poorly predicted by the existing models
  - Reflect on published work and OECD
  - Interrogate in vivo variability; build on Luechtefeld et al. 2016 and others
- Investigate incorporation of other data inputs
- Consider machine learning and other computational approaches, where feasible

# Ocular and Dermal Implementation Plan:

- Coordinate activities via the ICCVAM Workgroups
- Draft a scoping document to identify U.S. agency requirements, needs, and decision contexts for Ocular and Dermal data
- Coordinate efforts with stakeholders
- Identify, acquire, and curate high quality data from reference test methods
- Identify and evaluate non-animal alternative approaches to Ocular and Dermal testing
- **Gain regulatory acceptance and facilitate use of non-animal approaches**

# IATA for Eye Irritation: An International Effort

- OECD Guidance Document 263 (US and EU co-led project)
- Three parts:
  1. Existing and available information (physchem properties QSAR, read across, bridging)
  2. Weight of evidence
  3. New testing (in vitro and/or in vivo)



# Scientific and Non-scientific Challenges

- Animal methods currently provide the reference data for evaluating alternatives
  - Results are variable
  - Need to identify summary metric & characterize uncertainty
- Data requirements vary across U.S. and global regulatory authorities and are often ambiguous
- Overcoming institutional inertia
  - Education and training, communication with method/model developers